Tisento Therapeutics
Jennifer Chickering is an accomplished medical and clinical strategy leader with extensive experience in the biopharmaceutical industry. Currently serving as Vice President of Program Leadership at Tisento Therapeutics since July 2023, Jennifer previously held various leadership roles at Cyclerion, including Vice President and Senior Director of Clinical Strategy. Jennifer's career also includes key positions at Ironwood Pharmaceuticals, where responsibilities spanned from Director of Clinical Strategy to Senior Medical Writer. Prior to these roles, Jennifer operated as a Contract Medical Writer for 15 years. Jennifer holds a Doctor of Philosophy (PhD) in Ecology and Evolutionary Biology from Brown University and a Bachelor of Science (BS) in Biology from Rhodes College.
This person is not in any teams
This person is not in any offices
Tisento Therapeutics
Ti sento means “I hear you" in Italian. At Tisento Therapeutics, we believe that meaningful innovation requires understanding the problem, and that starts with listening. First and foremost, we listen to those impacted by debilitating diseases to understand the daily challenges they face. We also listen to healthcare providers, patient advocates, regulatory agencies, and scientific data. All these inputs inform our thinking and shape how we conduct our research, design our trials, and evolve our company. We are on a mission to deliver medicines that address what matters most. Our lead candidate is zagociguat (formerly CY6463), a Phase 2, first-in-class, brain-penetrant sGC stimulator, which is advancing in MELAS and other genetic mitochondrial diseases. Zagociguat is ideally suited to treat mitochondrial diseases with both CNS and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness.